Join PDS Biotechnology for a virtual key opinion leader (KOL) event featuring Jonathan M. Hernandez, M.D. (Investigator, Surgical Oncology Program, NCI/CCR) who will join company management to discuss the PDS0301 Phase 2 trials for the treatment of advanced liver-associated cancers with a focus on metastatic colorectal cancer (mCRC).

The event will provide an overview of the PDS0301 trials that are in unresectable microsatellite stable (MSS) or mismatch repair-proficient (pMMR) colorectal liver metastases, constituting the majority of mCRC. PDS0301 is an investigational IL-12 immunocytokine designed using an antibody that binds to necrotic DNA that is found within tumors. PDS0301 specifically targets and delivers the IL-12 into the tumor to promote T cell and natural killer (NK) cell infiltration into the tumor, as well as localized anti-tumor activation of both T cells and NK cells.

The Company anticipates the submission of a registrational Phase 3 clinical trial protocol for PDS0301 in the near future.

A live question and answer session will follow the formal presentations.